Targeting specific signaling pathways to treat advanced prostate cancer
Targeting the Plk1/Pdcd4/mTORC2 Signaling to Treat Castration-Resistant Prostate Cancer
This study is looking at how certain signals in the body can be used to create better treatments for men with castration-resistant prostate cancer, especially for those who haven't had success with current therapies.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Kentucky NIH-funded |
| Lab location | 1 site (Lexington, United States) |
| Project ID | NIH-10857196 on NIH RePORTER |
What this research studies
This research focuses on understanding how certain signaling pathways, specifically the Plk1/Pdcd4/mTORC2 pathway, can be targeted to improve treatment for patients with castration-resistant prostate cancer (CRPC). The study aims to explore the role of the tumor suppressor Pdcd4 and its interaction with Plk1, a key regulator of cell cycle events, to find new therapeutic strategies for patients who do not respond to current androgen signaling inhibitors. By identifying these pathways, the research seeks to develop more effective treatment options for CRPC patients, potentially enhancing their response to therapy.
Who could benefit from this research
Good fit: Ideal candidates for this research are men diagnosed with castration-resistant prostate cancer who have not responded to standard androgen signaling inhibitors.
Not a fit: Patients with early-stage prostate cancer or those who are responsive to current androgen signaling therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options for patients with advanced prostate cancer who have become resistant to existing therapies.
How similar studies have performed: Previous research has shown promise in targeting similar pathways in cancer treatment, indicating potential for success in this approach.
Where this research is happening
Lexington, United States
- University of Kentucky — Lexington, United States (Active)
Researchers
- Principal investigator: Liu, Xiaoqi — University of Kentucky
- Study coordinator: Liu, Xiaoqi
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.